• Co-pay amounts may vary—Maximum savings limit applies
  • Patient’s out-of-pocket expenses may vary
  • Patients whose prescriptions are covered under Medicare, Medicaid, or other government programs are not eligible
  • Cash-paying patients are not eligible

*Maximum savings of $150 per prescription. Restrictions apply.

Please see Eligibility Requirements, and Terms and Conditions below.

For questions, call 844-SYMPROIC (844-796-7764)

Eligibility requirements

This card cannot be used if your prescriptions are covered by: (i) any federal or state healthcare program, including a state medical or pharmaceutical assistance program (Medicare, Medicaid, Medigap, VA, DOD, TRICARE, etc); (ii) Medicare Prescription Drug Program (Part D Program); or (iii) insurance in states that have an “all payor” anti-kickback law or insurance that is paying the entire cost of the prescription. Void where prohibited by law. Patients must meet eligibility requirements. Other restrictions may apply. Cash-paying patients are not eligible.


Patients must meet eligibility requirements. Patient agrees to report their use of this card to any third party that reimburses or pays for any part of the prescription price. Patient additionally agrees to not submit any portion of the product dispensed pursuant to this card to a federal or state healthcare program for purposes of counting it toward their out-of-pocket expenses (such as TrOOP under Medicare Part D or Medicaid). Depending on insurance coverage, most eligible patients may pay as little as $0 on each prescription. Maximum savings limits apply; patient’s out-of-pocket expenses may vary. This card is not valid with any other program, discount, or incentive involving the covered medication. This offer is good for 13 uses and can only be applied to prescriptions of 20 tablets or more. This offer is not contingent upon any past, present, or future purchases of the covered drug or any other product, and this offer may be rescinded, revoked, or amended without notice. No reproductions. This card is not insurance. This card is void where prohibited or where restricted beyond the terms herein.


A valid prescription must accompany this card at time of first use. Tell your patients to retain their Symproic Savings Card for future savings during the time of offer throughout the program period. Treat these materials like you would a blank prescription pad. Hand them out yourself and don't leave them in the general waiting areas of your office.

The Symproic Savings Card is accepted at participating pharmacies. Certain pharmacies are able to deduct the savings without the Symproic Savings Card. For a list of these pharmacies, go to http://evoucherrx.relayhealth.com/storelookup/.

Please read the Full Prescribing Information. Also, please read the Eligibility Requirements, and Terms and Conditions above.


CoverMyMeds partners with electronic health records (EHRs), payers, pharmacies, and providers to initiate, transmit, and track the status of prior authorization (PA) requests within the clinical workflow.

CoverMyMeds technology electronically connects providers, pharmacists, and plan/pharmacy benefit managers (PBMs) to create an ePA solution for all participations.

For more information please visit www.CoverMyMeds.com or call (866) 452-5017.



SYMPROIC® (naldemedine) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.

Important Safety Information


  • Patients with known or suspected gastrointestinal (GI) obstruction and patients at increased risk of recurrent obstruction, due to the potential for GI perforation.
  • Patients with a history of a hypersensitivity reaction to naldemedine. Reactions have included bronchospasm and rash.

Warnings and Precautions

Cases of GI perforation have been reported with use of another peripherally acting opioid antagonist in patients with conditions that may be associated with localized or diffuse reduction of structural integrity in the wall of the GI tract. Monitor for the development of severe, persistent, or worsening abdominal pain; discontinue if this symptom develops.

Symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, increased lacrimation, hot flush/flushing, pyrexia, sneezing, feeling cold, abdominal pain, diarrhea, nausea, and vomiting have occurred in patients treated with SYMPROIC®.

Patients having disruptions to the blood-brain barrier may be at increased risk for opioid withdrawal or reduced analgesia. Take into account the overall risk-benefit profile when using SYMPROIC® in such patients. Monitor for symptoms of opioid withdrawal in such patients.

Drug Interactions

Avoid use with strong CYP3A inducers (e.g., rifampin) because they may reduce the efficacy of SYMPROIC®.

Use with moderate (e.g., fluconazole) and strong (e.g., itraconazole) CYP3A inhibitors and P-glycoprotein inhibitors (e.g., cyclosporine) may increase SYMPROIC® concentrations. Monitor for potential adverse reactions.

Avoid use of SYMPROIC® with another opioid antagonist due to the potential for additive effect and increased risk of opioid withdrawal.

Use in Specific Populations

Naldemedine crosses the placenta and may precipitate opioid withdrawal in a fetus due to the immature fetal blood-brain barrier. SYMPROIC® should be used during pregnancy only if the potential benefit justifies the potential risk. Because of the potential for serious adverse reactions, including opioid withdrawal in breastfed infants, a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Avoid use in patients with severe hepatic impairment. No dose adjustment of SYMPROIC® is required in patients with mild or moderate hepatic impairment.

Adverse Reactions

The most common adverse reactions with SYMPROIC® compared to placebo in two pooled 12-week studies were: abdominal pain (8% vs 2%), diarrhea (7% vs 2%), nausea (4% vs 2%), and gastroenteritis (2% vs 1%).

The incidence of adverse reactions of opioid withdrawal in two pooled 12-week studies was 1% (8/542) for SYMPROIC® and 1% (3/546) for placebo. In a 52-week study, the incidence was 3% (20/621) for SYMPROIC® and 1% (9/619) for placebo.

Please see Full Prescribing Information and Medication Guide for SYMPROIC®.

To report suspected Adverse Reactions, contact BioDelivery Sciences International, Inc. at 1-800-469-0261 or FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.